Related Experiment Video
Updated: May 20, 2026
11:08
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
Published on: June 22, 2012
Thrombotic microangiopathy and associated renal disorders
Thomas Barbour1, Sally Johnson, Solomon Cohney
1Imperial College, Centre for Complement and Inflammation Research, London, UK. t.barbour@imperial.ac.uk
Summary
Thrombotic microangiopathy (TMA) involves low platelets, red blood cell destruction, and blood clots. Understanding its diverse causes and renal effects is key for diagnosis and emerging treatments.
Area of Science:
- Nephrology
- Hematology
- Pathology
Background:
- Thrombotic microangiopathy (TMA) encompasses conditions like hemolytic uremic syndrome (HUS), atypical HUS (aHUS), and thrombotic thrombocytopenic purpura (TTP).
- These disorders share features of thrombocytopenia, microangiopathic hemolytic anemia, and microvascular occlusion, often leading to diagnostic challenges.
- Shiga toxin-producing E. coli (STEC)-HUS is a major cause of acute kidney injury in children globally.
Purpose of the Study:
- To review the current understanding of TMA's molecular mechanisms and clinical manifestations, focusing on renal involvement.
- To present an updated diagnostic and therapeutic approach based on international guidelines and recent research.
- To discuss emerging therapies and management strategies for TMA.
Main Methods:
- Review of international guidelines, disease registries, and published clinical trials.
- Analysis of molecular mechanisms underlying different TMA subtypes.
- Correlation of pathogenic pathways with clinical presentations, particularly renal manifestations.
Main Results:
- Dysregulation of the alternative complement pathway is implicated in aHUS.
- Reduced ADAMTS13 activity and von Willebrand factor abnormalities characterize TTP.
- Current empirical treatments include plasma exchange, with specific exceptions for STEC-HUS and pneumococcal sepsis.
Conclusions:
- Despite overlapping clinical features, understanding distinct molecular pathways is crucial for TMA diagnosis.
- Emerging therapies like eculizumab for aHUS and rituximab for TTP offer new treatment avenues.
- Renal transplantation is an option for dialysis-dependent patients with aHUS.
Related Concept Videos
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:24Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...